

# Roger G Pertwee

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8725700/roger-g-pertwee-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180  
papers

20,451  
citations

69  
h-index

142  
g-index

214  
ext. papers

22,500  
ext. citations

6.3  
avg, IF

7.28  
L-index

#	Paper	IF	Citations
180	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. <i>Biochemical Pharmacology</i> , <b>1995</b> , 50, 83-90	6	2266
179	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. <i>Pharmacological Reviews</i> , <b>2010</b> , 62, 588-631	22.5	1159
178	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. <i>British Journal of Pharmacology</i> , <b>2008</b> , 153, 199-215	8.6	1082
177	Pharmacology of cannabinoid CB1 and CB2 receptors <b>1997</b> , 74, 129-80		1074
176	Cannabinoid receptors and pain. <i>Progress in Neurobiology</i> , <b>2001</b> , 63, 569-611	10.9	581
175	Cannabinoids control spasticity and tremor in a multiple sclerosis model. <i>Nature</i> , <b>2000</b> , 404, 84-7	50.4	462
174	Cannabinoid pharmacology: the first 66 years. <i>British Journal of Pharmacology</i> , <b>2006</b> , 147 Suppl 1, S163-78.	8.6	435
173	Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 769-76	8.3	402
172	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , <b>2019</b> , 176 Suppl 1, S21-S141	8.6	391
171	The pharmacology of cannabinoid receptors and their ligands: an overview. <i>International Journal of Obesity</i> , <b>2006</b> , 30 Suppl 1, S13-8	5.5	375
170	Allosteric modulation of the cannabinoid CB1 receptor. <i>Molecular Pharmacology</i> , <b>2005</b> , 68, 1484-95	4.3	371
169	Pharmacology of Cannabinoid Receptor Ligands. <i>Current Medicinal Chemistry</i> , <b>1999</b> , 6, 635-664	4.3	361
168	Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. <i>Life Sciences</i> , <b>2005</b> , 76, 1307-24	6.8	352
167	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. <i>British Journal of Pharmacology</i> , <b>2009</b> , 156, 397-411	8.6	339
166	Endocannabinoids control spasticity in a multiple sclerosis model. <i>FASEB Journal</i> , <b>2001</b> , 15, 300-2	0.9	330
165	Are cannabidiol and (9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. <i>British Journal of Pharmacology</i> , <b>2015</b> , 172, 737-53	8.6	327
164	Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. <i>British Journal of Pharmacology</i> , <b>1999</b> , 126, 665-72	8.6	314

163	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. <i>Journal of Medicinal Chemistry</i> , <b>1994</b> , 37, 1889-93	8.3	296
162	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. <i>Nature Medicine</i> , <b>2007</b> , 13, 492-7	50.5	292
161	Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. <i>FEBS Letters</i> , <b>2000</b> , 483, 52-6	3.8	290
160	Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2012</b> , 367, 3353-63	5.8	244
159	Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. <i>Current Medicinal Chemistry</i> , <b>2010</b> , 17, 1360-81	4.3	237
158	Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. <i>Addiction Biology</i> , <b>2008</b> , 13, 147-59	4.6	224
157	The perceived effects of smoked cannabis on patients with multiple sclerosis. <i>European Neurology</i> , <b>1997</b> , 38, 44-8	2.1	215
156	Early phytocannabinoid chemistry to endocannabinoids and beyond. <i>Nature Reviews Neuroscience</i> , <b>2014</b> , 15, 757-64	13.5	204
155	Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 323-33	3.8	204
154	Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. <i>British Journal of Pharmacology</i> , <b>2001</b> , 132, 631-40	8.6	194
153	The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. <i>AAPS Journal</i> , <b>2005</b> , 7, E625-54	3.7	166
152	Cannabidiol targets mitochondria to regulate intracellular Ca <sup>2+</sup> levels. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 2053-63	6.6	164
151	Endocannabinoids and Their Pharmacological Actions. <i>Handbook of Experimental Pharmacology</i> , <b>2015</b> , 231, 1-37	3.2	163
150	Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. <i>Neuropharmacology</i> , <b>2001</b> , 40, 221-32	5.5	158
149	Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 1553-71	5.9	157
148	GPR55: a new member of the cannabinoid receptor clan?. <i>British Journal of Pharmacology</i> , <b>2007</b> , 152, 984-6	8.6	151
147	Cannabinoids and multiple sclerosis <b>2002</b> , 95, 165-74		140
146	Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 2425-33	6.6	138

145	Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. <i>British Journal of Pharmacology</i> , <b>1996</b> , 118, 2199-205	8.6	134
144	Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. <i>Journal of Comparative Neurology</i> , <b>2002</b> , 448, 410-22	3.4	129
143	Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. <i>European Journal of Pharmacology</i> , <b>1997</b> , 339, 53-61	5.3	128
142	Interactions between synthetic vanilloids and the endogenous cannabinoid system. <i>FEBS Letters</i> , <b>1998</b> , 436, 449-54	3.8	126
141	Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. <i>British Journal of Pharmacology</i> , <b>2005</b> , 146, 917-26	8.6	125
140	Phytocannabinoids beyond the Cannabis plant - do they exist?. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 523-9	8.6	123
139	Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. <i>British Journal of Pharmacology</i> , <b>1997</b> , 121, 1557-66	8.6	116
138	Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. <i>Carcinogenesis</i> , <b>2010</b> , 31, 1584-91	4.6	114
137	(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. <i>European Journal of Pharmacology</i> , <b>2002</b> , 456, 99-106	5.3	113
136	Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. <i>Molecular Pharmacology</i> , <b>2008</b> , 73, 441-50	4.3	111
135	AM630, a competitive cannabinoid receptor antagonist. <i>Life Sciences</i> , <b>1995</b> , 56, 1949-55	6.8	111
134	Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. <i>Pediatric Research</i> , <b>2008</b> , 64, 653-8	3.2	108
133	Modulation of L-Elysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 91-104	5.4	106
132	Cannabidiolic acid prevents vomiting in <i>Suncus murinus</i> and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. <i>British Journal of Pharmacology</i> , <b>2013</b> , 168, 1456-70	8.6	105
131	Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. <i>British Journal of Pharmacology</i> , <b>2009</b> , 156, 1154-66	8.6	103
130	Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. <i>British Journal of Pharmacology</i> , <b>1996</b> , 118, 2053-8	8.6	101
129	The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 677-87	8.6	94
128	Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 301, 900-7	4.7	94

127	Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. <i>European Journal of Pharmacology</i> , <b>2000</b> , 401, 121-30	5.3	92
126	CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. <i>Molecular Pharmacology</i> , <b>2013</b> , 83, 322-38	4.3	91
125	Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2016</b> , 64, 359-81	9	89
124	Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. <i>Journal of Glaucoma</i> , <b>2006</b> , 15, 349-53	2.1	88
123	Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. <i>Neuropharmacology</i> , <b>2004</b> , 47, 1170-9	5.5	88
122	Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidiny)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 2700-10	8.3	88
121	Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. <i>Journal of Leukocyte Biology</i> , <b>2007</b> , 82, 532-41	6.5	85
120	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2008</b> , 193, 120-9	3.5	82
119	A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 30-7	8.6	76
118	Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. <i>British Journal of Pharmacology</i> , <b>1995</b> , 115, 869-70	8.6	74
117	The evidence for the existence of cannabinoid receptors. <i>General Pharmacology</i> , <b>1993</b> , 24, 811-24		74
116	Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. <i>Biological Psychiatry</i> , <b>2018</b> , 84, 722-733	7.9	72
115	Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. <i>ACS Chemical Neuroscience</i> , <b>2012</b> , 3, 400-6	5.7	71
114	Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. <i>Phytomedicine</i> , <b>2014</b> , 21, 631-9	6.5	70
113	Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. <i>Journal of Neuroscience Research</i> , <b>2011</b> , 89, 1509-18	4.4	69
112	Cannabidiol-induced intracellular Ca <sup>2+</sup> elevations in hippocampal cells. <i>Neuropharmacology</i> , <b>2006</b> , 50, 621-31	5.5	69
111	Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. <i>British Journal of Pharmacology</i> , <b>2004</b> , 143, 774-84	8.6	69
110	The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. <i>British Journal of Pharmacology</i> , <b>2007</b> , 150, 586-94	8.6	68

109	Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. <i>Progress in Lipid Research</i> , <b>2013</b> , 52, 80-109	14.3	65
108	Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. <i>Proceedings of the Nutrition Society</i> , <b>2014</b> , 73, 96-105	2.9	64
107	Cannabinoids and multiple sclerosis. <i>Molecular Neurobiology</i> , <b>2007</b> , 36, 45-59	6.2	64
106	Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. <i>ACS Chemical Neuroscience</i> , <b>2017</b> , 8, 1188-1203	5.7	63
105	Neuropharmacology and therapeutic potential of cannabinoids. <i>Addiction Biology</i> , <b>2000</b> , 5, 37-46	4.6	62
104	Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. <i>Life Sciences</i> , <b>1999</b> , 65, 597-605	6.8	61
103	Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. <i>AAPS PharmSci</i> , <b>1999</b> , 1, E4		59
102	Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. <i>European Journal of Pharmacology</i> , <b>1995</b> , 272, 73-8	5.3	58
101	Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. <i>Psychopharmacology</i> , <b>2011</b> , 215, 505-12	4.7	57
100	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3626-34	8.3	57
99	6"-Azidohehex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. <i>European Journal of Pharmacology</i> , <b>2004</b> , 487, 213-21	5.3	56
98	Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. <i>European Journal of Pharmacology</i> , <b>1995</b> , 284, 241-7	5.3	55
97	The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. <i>European Journal of Pharmacology</i> , <b>1994</b> , 259, R7-8	5.3	55
96	Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. <i>Neuropharmacology</i> , <b>1998</b> , 37, 1123-30	5.5	51
95	The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. <i>Journal of Medicinal Chemistry</i> , <b>1998</b> , 41, 5177-87	8.3	51
94	In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. <i>Behavioural Pharmacology</i> , <b>2014</b> , 25, 182-5	2.4	49
93	Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohehex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. <i>British Journal of Pharmacology</i> , <b>1999</b> , 128, 735-43	8.6	47
92	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. <i>Experimental Neurology</i> , <b>2015</b> , 273, 36-44	5.7	46

91	Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 44-60	8.3	46
90	Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. <i>British Journal of Pharmacology</i> , <b>1997</b> , 121, 1716-20	8.6	46
89	Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. <i>Psychopharmacology</i> , <b>2008</b> , 198, 551-63	4.7	46
88	Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 3221-9	8.3	46
87	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178 Suppl 1, S27-S156	8.6	46
86	Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. <i>Neuropharmacology</i> , <b>2013</b> , 75, 155-63	5.5	45
85	delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. <i>European Journal of Pharmacology</i> , <b>1993</b> , 250, 205-8	5.3	45
84	AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 2561-74	8.6	44
83	Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. <i>European Journal of Pharmacology</i> , <b>1994</b> , 259, 115-20	5.3	44
82	Pharmacological and therapeutic targets for $\Delta^9$ tetrahydrocannabinol and cannabidiol. <i>Euphytica</i> , <b>2004</b> , 140, 73-82	2.1	43
81	O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. <i>British Journal of Pharmacology</i> , <b>2000</b> , 129, 1577-84	8.6	43
80	Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 337, 104-9	3.4	42
79	Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. <i>British Journal of Pharmacology</i> , <b>2000</b> , 129, 645-52	8.6	42
78	WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. <i>Behavioural Brain Research</i> , <b>2010</b> , 208, 584-92	3.4	41
77	CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 8774-9	11.5	40
76	Agonist-antagonist characterization of 6'-cyanohept-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. <i>European Journal of Pharmacology</i> , <b>1996</b> , 315, 195-201	5.3	38
75	Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. <i>British Journal of Pharmacology</i> , <b>1998</b> , 125, 1345-51	8.6	36
74	Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 5915-28	8.3	35

73	Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT receptor-mediated suppression of nausea and anxiety in rats. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 100-112	8.6	35
72	The phytocannabinoid, $\Delta^9$ -tetrahydrocannabivarin, can act through 5-HT <sub>1A</sub> receptors to produce antipsychotic effects. <i>British Journal of Pharmacology</i> , <b>2015</b> , 172, 1305-18	8.6	32
71	Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens. <i>European Journal of Pharmacology</i> , <b>1996</b> , 296, 169-72	5.3	32
70	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 542-568	8.3	30
69	Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. <i>ACS Chemical Neuroscience</i> , <b>2016</b> , 7, 776-98	5.7	30
68	$\Delta^9$ -Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 2450-61	8.6	29
67	Relative pharmacological potency in mice of optical isomers of delta 1-tetrahydrocannabinol. <i>Biochemical Pharmacology</i> , <b>1974</b> , 23, 439-46	6	29
66	Identification of the First Synthetic Allosteric Modulator of the CB Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 276-287	8.3	28
65	Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus - longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca <sup>2+</sup> and camp. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>1998</b> , 76, 340-346	2.4	27
64	Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. <i>Neuroscience Letters</i> , <b>2006</b> , 408, 236-41	3.3	26
63	Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. <i>Psychopharmacology</i> , <b>2003</b> , 166, 40-50	4.7	26
62	Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. <i>Bioorganic and Medicinal Chemistry</i> , <b>2005</b> , 13, 5102-74	3.4	26
61	Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. <i>European Journal of Neuroscience</i> , <b>2007</b> , 25, 2093-102	3.5	25
60	Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. <i>Neuropharmacology</i> , <b>2005</b> , 48, 1139-46	5.5	25
59	Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. <i>Behavioural Brain Research</i> , <b>2006</b> , 168, 307-11	3.4	25
58	Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. <i>ChemMedChem</i> , <b>2012</b> , 7, 920-34	3.7	24
57	Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. <i>European Journal of Pharmacology</i> , <b>2011</b> , 651, 96-105	5.3	24
56	First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. <i>FEBS Letters</i> , <b>2006</b> , 580, 568-74	3.8	23



55	In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. <i>Pharmacological Research</i> , <b>2010</b> , 61, 349-54	10.2	22
54	Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 316, 955-65	4.7	22
53	Action of delta-9-tetrahydrocannabinol on GABA(A) receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice. <i>Neuropharmacology</i> , <b>1997</b> , 36, 1387-92	5.5	18
52	Development of agonists, partial agonists and antagonists in the 8-Tetrahydrocannabinol series. <i>Tetrahedron</i> , <b>1999</b> , 55, 13907-13926	2.4	18
51	Known Pharmacological Actions of Delta-9-Tetrahydrocannabinol and of Four Other Chemical Constituents of Cannabis that Activate Cannabinoid Receptors <b>2014</b> , 115-136		18
50	Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. <i>Behavioural Pharmacology</i> , <b>2015</b> , 26, 289-303	2.4	17
49	Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. <i>British Journal of Pharmacology</i> , <b>2013</b> , 169, 887-99	8.6	17
48	The In Vivo Effects of the CB-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2017</b> , 33, 582-590	2.6	17
47	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 58, 30-43	6.8	17
46	Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 3001-9	8.3	17
45	A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. <i>European Journal of Pharmacology</i> , <b>1995</b> , 272, 67-72	5.3	16
44	Big conductance calcium-activated potassium channel openers control spasticity without sedation. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 2662-2681	8.6	15
43	Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3312-8	8.3	15
42	Anticancer effects of n-3 EPA and DHA and their endocannabinoid derivatives on breast cancer cell growth and invasion. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2020</b> , 156, 102024	2.8	15
41	Pure Tetrahydrocannabivarin and a Cannabis sativa extract with high content in Tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. <i>Pharmacological Research</i> , <b>2016</b> , 113, 199-208	10.2	15
40	Known Pharmacological Actions of Nine Nonpsychotropic Phytocannabinoids <b>2014</b> , 137-156		14
39	Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 20781-2	11.5	14
38	Effect of delta 9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration. <i>European Journal of Pharmacology</i> , <b>1995</b> , 282, 251-4	5.3	13

37	Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. <i>Bioorganic and Medicinal Chemistry</i> , <b>2014</b> , 22, 4770-83	3.4	11
36	Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 109, 104407	5	9
35	The First Photochromic Affinity Switch for the Human Cannabinoid Receptor 2. <i>Advanced Therapeutics</i> , <b>2018</b> , 1, 1700032	4.9	9
34	Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors <b>2009</b> , 361-392		9
33	The Pharmacology and Therapeutic Potential of Plant Cannabinoids <b>2017</b> , 207-225		8
32	Tricyclic Fused Pyrazoles with a $\kappa$ -Click $\kappa$ ,2,3-Triazole Substituent in Position 3 Are Nanomolar CB1 Receptor Ligands. <i>Synthesis</i> , <b>2015</b> , 47, 817-826	2.9	8
31	Cannabidiol as a potential medicine <b>2005</b> , 47-65		8
30	$\kappa$ -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence. <i>British Journal of Pharmacology</i> , <b>2019</b> , 176, 4773-4784	8.6	7
29	Prescribing Cannabinoids for Multiple Sclerosis. <i>CNS Drugs</i> , <b>1999</b> , 11, 327-334	6.7	6
28	Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 8104-8126	8.3	6
27	Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers. <i>Organic and Biomolecular Chemistry</i> , <b>2017</b> , 15, 2086-2096	3.9	5
26	Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 257	6.1	5
25	Pyrazoles with a $\kappa$ -Click $\kappa$ -[N-(4-fluorobutyl)-1,2,3-triazole] substituent in position 3 are nanomolar CB1 receptor ligands. <i>Journal of Fluorine Chemistry</i> , <b>2014</b> , 167, 184-191	2.1	5
24	Inverse agonism at cannabinoid receptors. <i>International Congress Series</i> , <b>2003</b> , 1249, 75-86		5
23	Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats. <i>Brain Research Bulletin</i> , <b>2020</b> , 155, 166-173	3.9	5
22	The Cyclic AMP Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1412, 85-93	1.4	4
21	Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus - longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca <sup>2+</sup> and camp. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>1998</b> , 76, 340-346	2.4	4
20	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , <b>2019</b> , 2019,	1.7	4

19	Disease-associated polymorphisms within the conserved ECR1 enhancer differentially regulate the tissue-specific activity of the cannabinoid-1 receptor gene promoter; implications for cannabinoid pharmacogenetics. <i>Human Mutation</i> , <b>2020</b> , 41, 291-298	4.7	3
18	Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. <i>Cannabis and Cannabinoid Research</i> , <b>2021</b> , 6, 266-274	4.6	3
17	Fatty acid suppression of glial activation prevents central neuropathic pain after spinal cord injury. <i>Pain</i> , <b>2019</b> , 160, 2724-2742	8	3
16	Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators. <i>Cannabis and Cannabinoid Research</i> , <b>2016</b> , 1, 196-201	4.6	2
15	CB1 and CB2 Receptor Pharmacology <b>2008</b> , 91-99		2
14	Brain levels and relative potency of the 1,2-dimethylheptyl analogue of delta1-tetrahydrocannabinol in mice. <i>Biochemical Pharmacology</i> , <b>1974</b> , 23, 3017-27	6	2
13	Effects on the Post-translational Modification of H3K4Me3, H3K9ac, H3K9Me2, H3K27Me3, and H3K36Me2 Levels in Cerebral Cortex, Hypothalamus and Pons of Rats after a Systemic Administration of Cannabidiol: A Preliminary Study. <i>Central Nervous System Agents in Medicinal Chemistry</i> , <b>2021</b> , 21, 142-147	1.8	2
12	Cannabinoid Receptors and Their Ligands in Brain and Other Tissues <b>1999</b> , 177-185		2
11	Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 211, 113116	6.8	2
10	CB1 receptor binding sites for NAM and PAM: a first approach for studying, new n-butyl-diphenylcarboxamides as allosteric modulators. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 169, 106088	5.1	1
9	PSNCBAM-1 analogs: Structural evolutions and allosteric properties at cannabinoid CB1 receptor. <i>European Journal of Medicinal Chemistry</i> , <b>2020</b> , 203, 112606	6.8	1
8	Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. <i>Bioorganic and Medicinal Chemistry</i> , <b>2021</b> , 50, 116421	3.4	1
7	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. <i>Bioorganic and Medicinal Chemistry</i> , <b>2020</b> , 28, 115513	3.4	0
6	The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids <b>2008</b> , 637-686		0
5	The Displacement Binding Assay Using Human Cannabinoid CB2 Receptor-Transfected Cells. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1412, 57-63	1.4	
4	The function of the endocannabinoid system <sup>23-34</sup>		
3	New developments in the pharmacology of cannabinoids. <i>Pharmacochimistry Library</i> , <b>2002</b> , 249-258		
2	Pharmacology and potential therapeutic uses of some cannabinoids. <i>Future Neurology</i> , <b>2019</b> , 14, FNL28	1.5	

- 1 Assessing the treatment of cannabidiolic acid methyl ester: a stable synthetic analogue of cannabidiolic acid on c-Fos and NeuN expression in the hypothalamus of rats. *Journal of Cannabis Research*, **2021**, 3, 31 2.5